Shire logo

SHP - Shire Share Price

4690p 0.0  0.0%

Last Trade - 04/01/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £12.01bn
Position in Universe th / 1819
Bullish
Bearish
Unlock SHP Revenue
Momentum
Relative Strength (%)
1m +5.17%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
4,527 4,934 6,022 6,417 11,397 15,161 15,505 15,623 +27.3%
+5.5 +43.6 +160 -43.5 -53.8 +88.0 +393.3 +4.06
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2018, Shire Ltd revenues increased 5% to $11.56B. Net income before extraordinary items increased 50% to $1.73B. Revenues reflect Product Sales increase of 6% to $11.2B. Net income benefited from (Gain)/loss on sale of Oncology and prod increase from $400K to $267.2M (income), Integration and acquisition costs decrease of 27% to $512M (expense), Selling.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SHP Revenue Unlock SHP Revenue

Net Income

SHP Net Income Unlock SHP Revenue

Normalised EPS

SHP Normalised EPS Unlock SHP Revenue

PE Ratio Range

SHP PE Ratio Range Unlock SHP Revenue

Dividend Yield Range

SHP Dividend Yield Range Unlock SHP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SHP EPS Forecasts Unlock SHP Revenue
Profile Summary

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience Ophthalmology, Hematology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Directors
Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated January 28, 2008
Public Since May 23, 2008
No. of Shareholders: 5,265
No. of Employees: 23,044
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE4GD UK 50, FTSE Global 100, , ,
Exchange London Stock Exchange (Dual Listing)
Shares in Issue 918,120,398
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SHP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SHP
Upcoming Events for SHP
Frequently Asked Questions for Shire
What is the Shire share price?

As of 04/01/19, shares in Shire are trading at 4690p, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Shire share price performed this year?

Shares in Shire are currently trading at 4690p and the price has moved by 21.03% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Shire price has moved by 41.94% over the past year.

What are the analyst and broker recommendations for Shire?

Of the analysts with advisory recommendations for Shire, there are there are currently 3 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Shire is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Shire next release its financial results?

Shire is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-09-30
What is the Shire dividend yield?

The Shire dividend yield is % based on the trailing twelve month period.

Does Shire pay a dividend?

Last year, Shire paid a total dividend of 0.35, and it currently has a trailing dividend yield of %. Looking ahead, Shire has not announced an ex-dividend date yet.

When does Shire next pay dividends?

Shire has yet to annouce their ex-dividend date. The historic dividend yield on Shire shares is currently %.

How do I buy Shire shares?

To buy shares in Shire you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Shire?

Shares in Shire are currently trading at 4690p, giving the company a market capitalisation of £n/a.

Where are Shire shares listed? Where are Shire shares listed?

Here are the trading details for Shire:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: SHP
What kind of share is Shire?

We were not able to load our ranking data for Shire

Is there a Shire share price forecast 2020?

We were not able to load any forecast data for Shire.

How can I tell whether the Shire share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shire. Over the past six months, the relative strength of its shares against the market has been 33.88%. At the current price of 4690p, shares in Shire are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Shire PE Ratio?

We were not able to find PE ratio data for Shire.

Who are the key directors of Shire?

Shire's management team is headed by:

Flemming Ornskov - CEO
William Mordan - GCN
Perry Sternberg - OTH
Kim Stratton - OTH
Matthew Walker - OTH
Joanne Cordeiro - CHO
Thomas Dittrich - CFO
Andreas Busch - CSO
Anthony Ahern - DRC
Nigel Coffey - DRC
Paul Keogh - DRC
Anthony Grannell - DRC
James Dinniss - DRC
Who are the major shareholders of Shire?

Here are the top five shareholders of Shire based on the size of their shareholding:

Similar to SHP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.